oppn parties Will Serum Institute Profiteer By Selling To States And Private Hospitals At The Stated Rates?

News Snippets

  • 2nd ODI: Rohit Sharma roars back to form with a scintillating ton as India beat England by 4 wickets in a high scoring match in Cuttack
  • Supreme Court will appoint an observer for the mayoral poll in Chandigarh
  • Government makes it compulsory for plastic carry bag makers to put a QR or barcode with their details on such bags
  • GBS outbreak in Pune leaves 73 ill with 14 on ventilator. GBS is a rare but treatable autoimmune disease
  • Madhya Pradesh government banned sale and consumption of liquor at 19 religious sites including Ujjain and Chitrakoot
  • Odisha emerges at the top in the fiscal health report of states while Haryana is at the bottom
  • JSW Steel net profit takes a massive hit of 70% in Q3
  • Tatas buy 60% stake in Pegatron, the contractor making iPhone's in India
  • Stocks return to negative zone - Sensex sheds 329 points to 76190 and Nifty loses 113 points to 23092
  • Bumrah, Jadeja and Yashasvi Jaiswal make the ICC Test team of the year even as no Indian found a place in the ODI squad
  • India take on England in the second T20 today at Chennai. They lead the 5-match series 1-0
  • Ravindra Jadeja excels in Ranji Trophy, takes 12 wickets in the match as Saurashtra beat Delhi by 10 wickets. All other Team India stars disappoint in the national tournament
  • Madhya Pradesh HC says collectors must not apply NSA "under political pressure and without application of mind"
  • Oxfam charged by CBI over violation of FCRA
  • Indian students in the US have started quitting part-time jobs (which are not legally allowed as per visa rules) over fears of deportation
Manipur Chief Minister Biren Singh resigns after meeting Home Minister Amit Shah and BJP chief J P Nadda /////// President's Rule likely in Manipur
oppn parties
Will Serum Institute Profiteer By Selling To States And Private Hospitals At The Stated Rates?

By Sunil Garodia
First publised on 2021-04-24 03:34:51

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

Indian Express has reported that Serum Institute is going to sell the Covishield vaccine (developed by Oxford University and AstraZeneca and being contract-manufactured in India by Serum) to private hospitals in India at the world's highest rate. It has made a rate chart (see lead picture) which shows that while the vaccine is available all over the world at between $ 2.15 (Rs. 162 in the European Union) to $5.25 (Rs. 395 in South Africa and Saudi Arabia). Serum has said that it will sell at Rs. 400 per dose to state governments and at Rs. 600 per dose to private hospitals. Although it had sold the first 100 million doses to the Central government at Rs. 150 per dose, Adar Poonawala, the CEO of Serum had stated at that time that the final price for private markets would be Rs.1000 per dose. Yet, the company had said that it was making a small profit even while selling to the Centre at Rs. 150 per dose.

So is Poonawala not the angel he first seemed when his company took a calculated gamble and produced the vaccine "at-risk" even before it was approved and supplied the shots immediately when they were approved at probably the cheapest rate in the world? Should he and Serum be allowed to get away with making huge profits by now supplying the shots at prices much higher than other countries pay, especially when the Centre has ploughed in Rs 3000 crore as advance payment for it to ramp up production? This is interest-free tax payers money Serum is getting and it should keep this in mind before fixing the rates for the shots.

India is a huge market. If Covishield can be supplied between Rs 162 and Rs 300 per dose in the European Union and UK, one feels that anything between that should be the rate at which Serum should supply to both the Centre and the states. It can charge a little extra for private hospitals. Ideally, the Centre should negotiate a combined rate for itself and the states and it should not be more than Rs. 250 per dose. Serum can then price the doses at Rs. 300 for private hospitals. Making profits is the right of all commercial entities and Serum should be allowed to make reasonable profits for its enterprise. But profiteering cannot be tolerated, not even in normal times let alone in a pandemic.